MedTrace Logo

RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection

NCT04064632 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1609

Last updated 2019-08-22

No results posted yet for this study

Summary

This study evaluates efficacy and safety of rilpivirine as substitutive agent for the nucleosidic backbone of HAART in virologic suppressed patients when combined with cobicistat-boosted darunavir.

Conditions

  • HIV Infection

Interventions

DRUG

Rilpivirine + darunavir/cobicistat

Switch to a dual ART

Sponsors & Collaborators

  • San Raffaele University Hospital, Italy

    collaborator OTHER

  • A.O. Ospedale Papa Giovanni XXIII

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2019-06-13
Completion
2019-11-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04064632 on ClinicalTrials.gov